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ABSTRACT
This thesis aims to evaluate the utility of dynamic contrast enhanced computed
tomography (DCE-CT) imaging in conjunction with kinetic analysis (CT Perfusion)
for the investigation of fibrotic liver disease. Monte Carlo simulations and sensitivity
analysis of the kinetic model were used to characterize the bias, variance and
covariance of perfusion parameters calculated with CT Perfusion. DCE-CT scans
were performed on rats treated with carbon tetrachloride (CCI4) for 8 weeks to induce
liver fibrosis, as well as sham injected control rats. Perfusion parameters were then
derived from the DCE-CT scans using CT Perfusion.

CCI4

treated rats showed

significant changes in total hepatic blood flow, arterial hepatic blood flow, blood
volume, and arterial fraction of blood flow. Histological samples were collected at
various stages of treatment and stained with methyl blue. Digital image analysis was
used to quantify fibrosis content of stained tissue. A strong correlation was found
between fibrosis content and arterial fraction of blood flow (r=.82 p<.00001).

Keywords:

Dynamic Contrast Enhance Computed Tomography, DCE-CT, CT

Perfusion, Hepatic perfusion, Liver disease, Hepatic fibrosis, Cirrhosis, Hepatic blood
flow
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CHAPTER 1
INTRODUCTION AND BACKGROUND TO HEPATIC FIBROSIS AND CHIRROSIS

1.1

INTRODUCTION TO THE LIVER

The liver is a vital organ that has many functions within the body. The primary
functions include detoxification synthesis and production of substrates necessary for
metabolism of lipids and carbohydrates. Situated in the upper abdomen behind the
right ribcage and below the diaphragm, the liver blood flow is supplied by two
sources (See Figure 1.1). The portal vein supplies blood from the spleen, gut and other
mesentery, and accounts for approximately 75% of total liver blood flow. The
remaining 25% of liver blood flow is supplied from the hepatic artery ’. Owing to the
higher oxygen content of arterial blood, oxygen delivery to the liver is about equally
derived from the portal vein and hepatic artery.
The liver plays an essential role in metabolism and has numerous roles in the
body, including glycogen storage, decomposition of red blood cells, plasma protein
synthesis, hormone production, and detoxification. Unlike other organs, the liver
benefits from a substantial regenerative capability. If as much as fifty percent of its
overall mass is surgically removed or damaged by intoxication, the liver is still
capable of complete regeneration . This regenerative ability makes the liver
extremely resilient to toxins and disease, however, chronic liver injury over prolonged
periods will result in the replacement of normal healthy liver tissue with non
functioning scar tissue (fibrosis) and reduced liver function. This scarring disrupts the
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normal liver architecture, leading to a resistance to blood flow through the liver.
When the scarring progresses far enough that it encapsulates regenerating nodules of
liver parenchyma, the condition is referred to as cirrhosis. Cirrhosis is a potentially
life-threatening condition with serious complications. The following section describes
causes of cirrhosis and its complications

1.1.1 Liver Disease
The Canadian Liver Foundation estimates that 3 million Canadians, including
men, women and children, are currently living with some form of liver diseases. The
most common causes of liver disease in Canada are listed below:
• Viral infections such as hepatitis B, C and D virus (HBV, HCV, HDV)
• Non-alcoholic fatty liver disease
• Chronic alcoholism
• Genetic disorders such as hemochromatosis and Wilson disease
• Autoimmune disorders such as primary biliary cirrhosis or primary sclerosing
cholangitis
Treatment of liver disease can be labor intensive and costly 3. It is estimated that the
annual cost to treat HCV infected intravenous drugs users alone, in Canada, is
approximately $176,000,000. 4
No matter the etiology, the liver has a common innate wound healing response
to chronic liver injury characterized by fibrosis of the liver. If the cause of the insult
cannot be removed, fibrosis will progress to cirrhosis and eventually liver failure and
death.

3
Normally blood flow from the intestines and spleen is pumped through the
portal vein. The altered vasculature of a cirrhotic liver presents a large resistance to
blood flow. This resistance is measured as the pressure gradient between and the
portal vein and the inferior vena cava, also known as the hepatic venous pressure
gradient (HVPG). In a normal liver the HVPG is less than 5mmHg. A HVPG greater
than lOmmHg is known as portal hypertension 5. The major complications of portal
hypertension are ascites, gastrointestinal hemorrhage and renal dysfunction.
Ascites is the accumulation of fluid in the peritoneal cavity, driven by
increased capillary hydrostatic pressure within the splanchnic bed as a result of portal
hypertension. Ascites carries a risk of spontaneous bacterial peritonitis and sepsis.
Diuretics can be used to control the accumulation of fluids but as liver disease
progresses this becomes more difficult6. Ascites and the abnormal handling of sodium
in combination with altered systemic circulation leads to hepatorenal disease 6. Liver
transplant is the only long-term solution to hepatorenal disease, after which kidney
function returns to normal or near normal levels.7
When the HVPG is greater than lOmmHg, blood flow though the hepatic
portal venous system is redirected from the liver into areas with lower venous
pressures. This means that collateral circulation develops in the lower esophagus,
abdominal wall, stomach and rectum. The small, thin walled vessels become
distended and are at risk of rupture, causing the patient to bleed internally.
Portal hypertension and its complications are the leading cause of morbidity
and mortality in patients with cirrhosis.

o
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Hepatocellular carcinoma (HCC) is also a common complication for patients
with liver disease. It has been estimated that 80% of all HCC occurs in a cirrhotic
background9. The annual risk of developing HCC for patients with HCV infection has
been estimated to be 3-8%9.

1.2

MICROSTRUCTURE OF THE LIVER
The hepatocyte is the primary parenchymal cell of the liver, making up 80% of

the total hepatic cell population. They are arranged in unicellular plates, sometimes
referred to as Remak’s plates. These plates branch and anastamose with each other
forming a maze like arrangement of partitions. Between the plates of hepatocytes are
the liver sinusoids. Liver sinusoids can be regarded as unique capillaries. Unlike
typical capillaries, the sinusoids have a discontinuous endothelial layer and lack a
basement membrane 10. This endothelial layer is made up of specialized liver
sinusoidal endothelial cells (LSEC), which have groups of fenestrations (pores)
measuring 150-175 nm in diameter ". These fenestrations act as a dynamic filter for
fluids, solutes and particles, allowing only particles smaller than the fenestrae to reach
the parenchymal cell l0. Between the endothelial layer and the hepatocytes is the
space of Disse. This space is primarily filled with hepatocyte microvilli as can be seen
in Figure 1.2, which allows proteins and other components of plasma to be absorbed
by the hepatocytes. The hepatic stellate cell (HSC), also known as the Ito cell,
lipocyte or fat-storing cells, resides within the space of Disse. The HSC is the major
cell type involved in the pathogenesis of liver fibrosis, as is discussed in further detail
in section 1.3. Kupffer cells are resident liver macrophages within the sinusoidal
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space where they can phagocytose and destroy foreign material such as bacteria.
Blood flow at the microscopic level originates at the portal triads. The portal
triads consist of an arrangement of branches from the hepatic artery, portal vein, and
bile duct, as well as lymphatic vessels. Blood supplied by the hepatic artery and portal
vein passes through the sinusoids and empties into the central veins, which then
coalesce into the hepatic veins. Figure 1.3 shows a representation of the microvascular
structure of the liver.

1.3

HEPATIC FIBROSIS AND VASCULAR REMODELING
A great deal of progress has recently been made in understanding the

pathogenesis of hepatic fibrosis. Fibrosis, or scarring of the liver, is a wound-healing
response that engages a range of cell types and mediators to encapsulate injury.
Although acute injury will activate mechanisms of fibrogenesis, the sustained signals
associated with chronic liver disease caused by infection, drugs, metabolic disorders,
or immune attack are required for significant fibrosis to accumulate. Under certain
circumstances a normal, or mildly fibrotic liver may rapidly progress to cirrhosis over
several weeks or months. For example, patients with HCV receiving
immunosuppressant drugs after liver transplant can have high viral load resulting in a
rapid progression to cirrhosis . A similar situation exists in patients with human
immunodeficiency virus (HIV)/HCV co-infection l3.
The hepatic stellate cell is the primary cell in the liver responsible for excess
collagen synthesis during hepatic fibrosis14. Upon injurious stimuli the HSC
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undergoes ‘activation’ which is a complex transformation to a proliferative,
contractile, myofibroblast-like cell. In reviewing the mechanisms of hepatic fibrosis,
Firedman S. defined three stages of fibrosis based on the activation of stellate cells 15.
These stages are initiation, perpetuation, and resolution. Initiating stimuli include
paracrine signals such as reactive oxygen species from apoptotic hepatocytes, injured
cholangiocytes, macrophages, stellate cells, and inflammatory cells 16 17. Early injury
of LSECs stimulates the production of cellular fibronectin, as well as platelet derived
growth factor (PDGF), which has an activating effect on stellate cells18. Apoptosis has
also been implicated in the fibrogentic response19. Apoptotic proteins released from
hepatocytes are fibrogenic towards cultured stellate cells20,21.
These initial parcrine signaling pathways result in changes in gene expression
and phenotype allowing the now ‘activated’ HSC to respond to new stimuli leading to
perpetuation. The induction of type I collagen gene expression causes the HSC to
become directly fibrogenic

. In addition, PDGF and it’s receptor have been shown

to be rapidly induced in culture and in vivo 24 25, resulting in proliferation as well as
chemotaxis 26. The expression of PDGF by LSECs along with the mitogenic effect of
PDGF on HSCs results in an enhanced coverage of sinusoids by HSCs in vivo .
Contractility is another key feature of the activated HSC. HSC’s have been
demonstrated to have contractile capability both in-vivo and in-vitro

. This

contractile capability is mediated primarily by endothelian-1 (ET-1) and inhibited by
nitric oxide (NO) produced by LSECs 29 30. During liver injury, LSEC show impaired
generation of NO resulting in vasoconstriction .
The combination of proliferated HSCs covering the sinusoidal lumen, and their
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subsequent contraction from reduced NO production in LSECs, results in a
constricted sinusoidal space. This alteration in the normal vascular structure, in
combination with increased deposition of collagen, contributes to increased
intrahepatic sinusoidal pressure, portal hypertension, and it’s subsequent
•
•
77 99
complications

The activated HSC is not simply a fibrogenic cell, it also plays an important role
in vascular structural changes and angiogenesis in hepatic fibrosis. Angiogenesis is
the dynamic formation of new vessels from pre-existing vessels 33,34. Angiogenic
processes occur throughout the body and are associated with tissue damage, wound
healing and vascular remodeling. Thus, it should come as no surprise that
angiogenesis occurs concurrently with hepatic fibrosis. Stimulation of angiogenesis
during hepatic fibrosis is thought to come from several possible sources. Vascular
endothelial growth factor (VEGF) is produced by hepatocytes in response to hypoxia
i f

as well as an autocrine signaling loop within LSECs

'i f -

. Activated HSCs have

also been shown to express angiogenic factors such as VEGF and angiopoietin-1
•

•

^7

"20

HSCs and LSECs play a unique dual role in both fibrogenesis and angiogenesis as
part of a total wound healing response. As a result anti-angiogenic drugs originally
designed for cancer treatments have seen renewed interest for the treatment of hepatic
fibrosis and it’s complications. The inhibition of the PDGF signaling pathway by the
receptor tyrosine-kinase inhibitor Imatinib was capable of reducing portal pressure in
an animal model of cirrhosis

. Reduced portal pressure was primarily the result of

reduced sinusoidal coverage by HSCs, thus resulting in reduced constriction of the
sinusoids. Although portal pressure was reduced no reduction in fibrogenesis was
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observed 27 39.
The resolution phase is still not completely understood. With the removal of the
underlying cause of liver injury, activated HSCs may revert back to a quiescent state
or be cleared through an apoptotic pathway30. Reversibility of fibrosis and cirrhosis is
still a debated topic but recently there has been increasing evidence that fibrosis and
cirrhosis can resolve to at least some extent 40 41 42.
A strong motivation for the use of perfusion imaging in hepatic liver disease is
evident. The combination of vascular remodeling and the role of angiogenesis in the
development of cirrhosis mark it as a disease with significant vascular consequences.
One direct consequence of vascular changes in liver cirrhosis is portal hypertension.
Portal hypertension is a major complication of liver cirrhosis representing a primary
cause of death or liver transplant 5 43. Currently the only measure of portal
hypertension is the HVPG. This technique is highly invasive and impractical under
normal circumstances however, it is also currently the best predictor of complications
from cirrhosis and the development of HCC 43 44. Non-invasive dynamic contrast
enhanced magnetic resonance (DCE-MR) perfusion measurements have already been
correlated to the HVPG in cirrhotic patients 45. Further research into perfusion
imaging techniques may provide useful non-invasive biomarkers of fibrotic liver
disease. These biomarkers could be capable of predicting disease outcome and aid in
patient treatment planning.

1.4

HEPATIC CIRCULATION AND BLOOD FLOW REGULATION
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Roughly 25% of blood flow and 50% of oxygen is delivered to the liver from
the hepatic artery. The remaining 75% of blood flow and 50% of oxygen is supplied
from the portal vein. Total Hepatic blood flow is estimated to be approximately 2530% of cardiac output. Normal changes to hepatic blood flow can result from a
variety of conditions. Exercise and sleep have been shown to cause a decrease in
hepatic blood flow 46, while an increase in hepatic blood flow has been observed in
the postprandial state 47. Finally, hepatic blood flow tends to decrease with increasing
age 48.
Regulation of blood flow in the liver is governed through three different sites.
Arterial flow is controlled by terminal hepatic arterioles, which are richly supplied in
smooth muscles cells. Portal flow is dependent on the flow in the supplying organs
and thus, is determined by the arterioles of these organs (eg. spleen and mesentery).
Finally, liver sinusoids and terminal hepatic venules are a source of intrahepatic
resistance 47. Blood flow in the liver is influenced by both intrinsic and extrinsic
mechanisms.

1.4.1 Intrinsic hepatic bloodflow regulation
In autoregulation, increased arterial perfusion pressure results in hepatic artery
vasoconstriction, presumably because of a myogenic response of the arteriolar smooth
muscle to stretch imposed by the increased perfusion pressure [REF]. Pressure-flow
autoregulation in the hepatic arterial system exists to some extent in the postprandial
liver, but probably not in the fasted liver 49 50. There is no evidence of autoregulation
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in the portal venous system; instead of the nonlinear pressure-flow relationship
associated with autoregulation, there exists a linear pressure-flow relationship51.
Changes in the composition of the portal venous and systemic blood
composition affect liver blood flow. These changes include arterial hypoxemia 52,
systemic hypercapnia 53, and alkalosis 54. Hepatic arterial blood flow is increased by
decreased portal oxygen tension and pH 54.
A relationship between arterial and portal venous blood flow has long been
known to exist. It was demonstrated that an occlusion of the portal vein results in an
immediate rise in hepatic arterial blood flow 55. This response of increased hepatic
arterial blood flow in response to a decrease in portal blood flow is called the ‘hepatic
arterial buffer response’ (HABR) 56. Lautt et al. 57 suggested that a change in the
concentration of adenosine, a vasoactive molecule, was responsible for this
relationship. Adenosine is released at a constant rate in the space of Mall, which
contains the hepatic arterioles and portal venules, and its concentration is regulated by
washout into these vessels, principally the portal vein. Thus, a drop in portal blood
flow would induce an increase in the local concentration of adenosine, which would
in turn increase arterial blood flow 57. Conversely, an increase in portal flow would
increase clearance of adenosine, causing arterial vasoconstriction. As further
evidence, it has been shown in the rabbit that the adenosine receptor antagonist, 8phenyltheophylline, inhibited this response while, the adenosine uptake inhibitor,
dipyridamole potentiated the HABR . Although increases in hepatic arterial blood
flow result only in a partial compensation for decreased portal flow, oxygen delivery
is maintained, even in cirrhotic livers ,9. While portal perfusion has a large effect on

_
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arterial blood flow, the reverse is not true. Changes in hepatic arterial flow have not
been shown to cause significant changes in the portal venous flow .
Despite identifying adenosine as the clear regulator of the HABR, the exact
cell type or site of adenosine production, as well as the specific biochemical pathway
have yet to be identified. It is suggested that the adenosine involved with the HABR
and autoregulation is produced at a constant rate and secreted into the space of Mall.
This

adenosine

is

most

likely derived from demethylation of S-

adenosylhomocysteine, a reaction that is oxygen independent and is proposed to
account for basal adenosine production in the heart60.
Although the exact site of interaction of the hepatic artery and portal vein has
not been identified, it is clearly occurring at a very localized level. Lobular changes in
blood flow, due to selective ligation of the portal inflow, clearly demonstrates this 61.
When portal flow to a single lobe was reduced by ligation, an increase in portal flow
occured in the other lobes. The ligated lobe showed an increase in arterial blood flow
while the unligated lobes showed a decrease in arterial flow. This demonstrates
lobular independence of the HABR 61.
In patients with cirrhosis, the HABR is blunted . A reduction in portal
perfusion due to increased intrahepatic sinusoidal resistance has been observed in
cirrhotic patients . This sustained reduction in portal flow results in the continuous
activation of the HABR 64. Accordingly, the HABR could play a protective role in
hepatic circulation by maintaining oxygenation65.
The continuous activation of the HABR in patients with fibrotic liver disease
provides a potential target for evaluating the stage of liver disease as well as the risk
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of complications. The continuous, adenosine mediated, activation of the HABR has
been implicated in the development of hepatorenal disease 66, which is a severe
complication of liver disease that can result in death. Currently, perfusion imaging
techniques are the only non-invasive way to regionally measure hemodynamic
changes in the liver that are consistent with the HABR. This thesis attempts to
measure hemodynamic changes in a rat model of liver fibrosis using dynamic contrast
enhanced CT (DCE-CT) scanning or CT Perfusion.

1.4.2 Extrinsic hepatic bloodflow regulation
Branches of the vagus, splanchnic, and sometimes phrenic nerves enter the
liver mainly in association with the blood vessels and bile ducts. The sympathetic and
parasympathetic nerves form an intercommunicating plexus, which terminates on
arterioles and venules. Functional vagal innervation does exist in the dog and
influences regional distribution within the liver by exerting effects on presinusoidal
sphincters 67, rather than by affecting total liver blood flow.
Of the systemic hormones, epinephrine is the most likely to attain vasoactive
concentrations physiologically. Both alpha and beta-adrenergic receptors are present
in the hepatic arterial bed, whereas only alpha receptors exist in the portal vasculature
/TO

Thus, epinephrine injected directly into the hepatic artery initially induces

vasoconstriction via the alpha receptors, followed by vasodilation mediated by the
beta receptors; the portal bed only vasoconstricts in response to intraportal
epinephrine.
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Glucagon causes a graded and long-lasting hepatic arterial vasodilation and
can antagonize the hepatic arterial vasoconstrictor responses to a wide range of
physiologic stimuli, including stress-induced sympathoadrenal outflow 69.
Angiotensin II evokes profound vasoconstriction of both hepatic arterial and portal
beds, together with a significant reduction in mesenteric outflow, and this translates
into a substantial reduction in total liver blood flow 70. Vasopressin also induces
marked splanchnic vasoconstriction; consequently, reduction in venous outflow into
the portal system and a reduction in inflow resistance in the portal vasculature
occurring after vasopressin administration make this hormone very effective in
alleviating portal hypertension .

1.5

ANIMAL MODELS OF LIVER FIBROSIS AND CIRRHOSIS
Several experimental models of hepatic fibrosis have been developed. These

include chemically induced fibrosis using hepatotoxic agents such as carbon
tetrachloride (CCI4) 72, dimethylnitrosamine 73 and thioacetamide 74, immunological
damage , biliary fibrosis via common bile duct ligation , and alcoholic liver disease
such as the Tsukamoto/French model in rats77.
Carbon tetrachloride is the most commonly used toxin-based experimental
model of liver fibrosis. It can be easily administered to rodents by inhalation, gastric
gavage, and subcutaneous or intraperitoneal injections 11. The trichloromethyl radical,
a metabolite produced by cytochrome P450 in hepatocytes leads to lipid peroxidation
and membrane damage , which results in acute centrilobular liver necrosis. CCI4
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models of liver fibrosis have the advantage of being well characterized with respect to
the histological and biochemical changes associated with injury, inflammation, and
fibrosis77,78. A further asset of CCI4 models for in vivo animal studies is the ability to
elicit a predictable and reproducible response. The administration of barbiturates in
drinking water can enhance the activation of cytochrome p450, enhancing CCI4 liver
injury, and is a common method of hastening the development of fibrosis. With a
combination of barbiturates and CCI4 treatment, development of fibrosis can occur in
as few as four weeks, and cirrhosis as early as eight weeks.
CCI4

models do have limitations. First, there is no direct human disease

counterpart , and second, there is a failure to progress to the development of
hepatocellular carcinoma unlike the dimethylnitrosamine model of fibrosis 79.
Although depending on the requirements of the fibrosis model, lack of cancerous
progression could also be viewed as an advantage.
A combination of CCI4 and the barbiturate, phénobarbital, are used in this thesis
to develop fibrosis and cirrhosis in rats. A detailed description of the methodology can
be found in chapter 3.

1.6

NON-INVASIVE METHODS FOR THE INVESTIGATION OF

HEPATIC FIBROSIS AND CIRRHOSIS
The current gold standard for assessing fibrosis is liver biopsy through a
percutaneous, transjugular, laparoscopic, or fine-needle approach. This invasive
method can be painful and carries a small but significant risk of serious
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80. Further limitations come with the analysis liver biopsy samples.
complications
Histological grading is not reproducible; there are both intra- and inter-observer
variability on small sized or fragmented biopsy samples . Because of these
limitations, biopsy is an impractical method for the regular monitoring of liver
fibrosis. As new anti-fibrotic treatments are developed, there is a growing need for
non-invasive methods of evaluating these treatments, as well as monitoring the
progression of hepatic fibrosis in patients. The most promising methods currently
under development are reviewed below.

1.6.1 Serum indices
Serum markers can be divided into direct and indirect markers of fibrosis.
Direct markers are fragments of the liver matrix components produced by HSCs
during the development of fibrosis, and the molecules involved in regulating the
progression of fibrosis. These include hyaluronic acid, collagens IV and VI, and
amino terminal fragment of procollagen III. Indirect markers of fibrosis include
molecules released into the blood due to liver inflammation, such as alanine
aminotransferase (ALT) and aspartate aminotransferase (AST), molecules
synthesised, regulated or excreted by the liver (such as clotting factors, cholesterol
and bilirubin), and processes that become deranged as liver function becomes
impaired, such as insulin resistance. Both direct serum markers, and indirect serum
markers have been thoroughly investigated

. When these markers are used

individually they can reasonably diagnosis or exclude cirrhosis but lack the ability to
differentiate intermediate stages of fibrosis. To increase diagnostic capability,

16
algorithms combining multiple serum markers, such as Fibrotest or the Enhanced
Liver Fibrosis (ELF) test have been proposed to improve diagnostic accuracy. In a
meta-analysis Fibrotest was able to distinguish between METAVIR stages ^ 1 vs
^F2 or ‘clinically significant’ fibrosis with area under the receiver operating
characteristic curve (AUROC) of .84 87. Currently, the ability to measure direct serum
markers is not routinely available in most hospitals. Additionally, direct serum
markers are not liver specific thus; they require patient specific considerations to be
taken into account when interpreting the results.

1.6.2 Transient elastography
Transient elastography is performed with an ultrasound transducer probe
mounted on the axis of a vibrator. A vibration transmitted from the vibrator toward
the tissue induces an elastic shear wave that propagates through the tissue. The
velocity of the shear wave is then measured using pulse-echo ultrasound acquisitions.
The harder the tissue, the faster the shear wave propagates 88. Transient elastography
is advantageous in that it can be repeatedly performed, does not require a highly
experienced operator, and has a low risk of complications. Results of several recent
studies have shown that measurement of liver stiffness with transient elastography is
excellent for the diagnosis of cirrhosis, but lacks sensitivity and specificity for the
intermediate stages of fibrosis . The reproducibility of transient elastography is also
•

OQ

substantially reduced in patients with steatosis and increased body mass index (BMI),
as well as patients with ascities. This is because ultrasonography itself has limitations
for clearly visualizing the liver in such patients. 90
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1.6.3 Magnetic resonance elastography (MRE)
MRE is a promising non-invasive method for monitor the progression of liver
fibrosis. MRE typically uses vibrations generated by external driver devices within
the audio frequency range to induce shear waves in the liver. A signal generator
triggered by and synchronized to the MR pulse sequence creates the electrical signal
for these devices. A modified phase-contrast technique is used to image the
propagation characteristics of the acoustic shear waves 91 92. The technique is easily
implemented on a conventional MRI system with modest additional hardware and
software. Several studies have demonstrated the excellent diagnostic capability of
MRE to stage liver fibrosis 93 94 9S, but activity of the underlying cause and steatosis
seem to influence measurements 95.
While MR elastography is a promising new method for staging liver disease it
does not provide vital functional information about the liver. For the evaluation of
new anti-fibrotic treatments a reduction in fibrotic content and reduced liver stiffness
may not necessarily indicate successful treatment. For a patient with portal
hypertension, a reduction in fibrosis content and liver stiffness is not clinically
relevant unless it is accompanied by hemodynamic changes that alleviate the portal
hypertension. Reversal of hemodynamic changes must accompany the reduction in
fibrosis content for treatment to be completely successful.

1.6.4 Dynamic contrast enhanced computed tomography (DCE-CT)
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Dynamic contrast enhance computed tomography (DCE-CT) was developed in
the late 1970s, with the aim of studying hemodynamics in tissue 96. However, spatial
and temporal resolutions of early hardware limited the widespread acceptance of
DCE-CT. Advancements in CT scanning technology over the years has addressed
these issues. The implementation of slip ring technology has increased temporal
resolutions to the sub-second mark. Detector technology has also progressed, allowing
DCE-CT imaging of whole organs, such as the liver, in a single study. These
advancements have allowed DCE-CT to become a more competitive imaging
modality, as well as to gain wider clinical acceptance. Some of the benefits of DCECT include its widespread availability in hospitals, its rapid scan times, with excellent
spatial and temporal resolution, and its ability to image soft tissues, bone and blood
vessels. Drawbacks of DCE-CT include use of contrast agents, which can impair renal
function, and the exposure to carcinogenic ionizing radiation.
DCE-CT has become a valuable clinical and research tool in the study of
angiogenesis and vascular changes associated with cancer and stroke diseases 97 98.
Various methods have been developed to measure hepatic perfusion in vivo. These
include Doppler ultrasound (US) 45, dynamic contrast enhanced magnetic resonance
(DCE-MR)99 and DCE-CT 97. Compared to Doppler US, which is capable of
measuring blood flow velocity in large vessels, DCE-CT is able to measure perfusion,
blood volume, mean transit time, and capillary permeability surface area product in a
single study97 In addition to this, DCE-CT can provide regional information that
Doppler ultrasound can not. This set of functional parameters provides a more
complete evaluation of tissue hemodynamics .
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The use of MR as a modality for perfusion techniques seems appealing due to
the lack of ionizing radiation. However, MR lacks a linear relationship between the
concentration of the gadolinium-based contrast agent and MR signal intensity. This
fact along with velocity-induced signal intensity changes in larger vessels has created
difficulties in obtaining quantitative perfusion data with DCE-MR 10°. In contrast, the
relationship between iodine concentration and x-ray attenuation during DCE-CT
examination is linear.
The maximum slope method for calculating liver perfusion is a commonly
used method based on the Fick Principle 10°. If F is blood flow and Ca(t) is the contrast
concentration at the arterial inlet and Cv(t) the contrast concentration at the venous
outlet then:

QiT) = F -)[C „ -C ,}d t
0

(1)

Where Q(t) is the contrast concentration in the tissue at time T. If T is less than the
minimum transit time of the contrast agent through the capillaries, then one can
assume no venous outflow and thus,

Q(T) = F-}c.-dt
0

(2)

or,

dQ{t)

= F C a(T)

(3)

The rate of contrast accumulation in the tissue, dQ(t)/dt, will be maximal when the
arterial concentration is maximal. Solving for blood flow gives,
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dQ(l)
F1 t=T = dl
CM

(4)

The ratio of the maximum rate of contrast accumulation, or maximum slope of
dQ(t)/dt to the maximum arterial concentration is equal to the blood flow.
The liver however, receives blood flow from both the hepatic artery and the
portal vein, which further complicates the calculation. The tissue concentration curves
from each blood flow source are overlaid, because the arrival of the contrast from the
portal vein arrives seconds after the contrast from the hepatic artery. To separate the
two concentration curves one can use the concentration curve from the spleen.
Because of the arrival time of the contrast agent through the body, one can assume
that peek enhancement of the spleen occurs after the maximum rate of change of the
contrast concentration in the liver tissue. Knowing this, the hepatic arterial blood flow
can simply be calculated by the maximum slope of the tissue concentration curve,
before peak splenic enhancement, divided by the peak hepatic arterial concentration,
Ca(t)max- Calculation of portal perfusion is more complex because the initial slope of
the portal concentration curve is overlaid by the hepatic arterial concentration curve.
If one assumes that the liver and spleen show similar contrast agent dynamics
during he arterial phase then the ratio of the hepatic arterial blood flow to the splenic
blood flow should be equal to the ratio of their concentration curves. Hence, a model
curve of pure arterial hepatic enhancement is computed by multiplying the splenic
time-concentration curve by the ratio of the maximum arterial liver gradient to the
maximum splenic gradient of the time-attenuation curves. This model curve is then
subtracted from the original hepatic concentration curve, Q(t), resulting in a portal
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venous concentration curve of the liver, Qpv(t), separate from its arterial component.
Portal perfusion can then be calculated from dQpv(t)/dt divided by the the peak of the
portal venous concentration curve Cpv(t).
The maximum slope method has two main drawbacks. First the no venous
outflow assumption may not always hold true, especially in a cirrhotic liver, which
can have substantial shunt formation 101. Second the use of the splenic concentration
curve to model the hepatic arterial concentration curve has not been validated.
CT Perfusion (GE healthcare) is a commercially available software package
capable of analyzing DCE-CT datasets. It has been validated in the rabbit liver using
radioactive microspheres as the gold standard 102, as well as in brain tumor 103 and
VX2 thigh tumors104.
With its ability to assess hemodynamics in a non-invasive fashion, DCE-CT
offers a way of tracking the progression of hepatic fibrosis and cirrhosis in vivo 102.
This thesis attempts to evaluate the utility of DCE-CT coupled with CT Perfusion in
the assessment of fibrotic liver disease. This is done using Monte Carlo simulation
techniques as well as correlating CT Perfusion parameters to fibrotic content in a CCU
rat model of hepatic fibrosis.
DCE-CT studies were performed on rats with a clinical multi-slice CT scanner
(Discovery VCT, GE Healthcare). At DCE-CT examination, an iodinated contrast
agent is injected via a peripheral vein while the CT scanner is used to measure the
passage of contrast through the vasculature and the uptake of contrast in the
extravascular (Disse) space, followed by the subsequent washout. In the analysis of
the DCE-CT data there are two fundamental underlying assumptions. The first is that
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the iodinated contrast agent is uniformly distributed throughout the vascular system
and the second is that the enhancement (increase in attenuation) of a particular tissue
is proportional to the concentration of the contrast agent in the tissue.
A localization scan was first performed to place eight 5mm slices covering the
entire rat liver. After the scan location was selected the DCE-CT scan was conducted
in two phases. In the first phase, images were acquired in cine mode under breath hold
by turning off the ventilator with a tube voltage and current of 120kVp and 80mA
respectively and a gantry speed of one rotation per second. Images were reconstructed
using the detail reconstruction filter and a temporal resolution of 0.45 seconds. Total
time for the first phase cine scan was 34 seconds. In the second phase the ventilator
was turned on with a breath rate of 80 breaths per minute and animals were scanned in
cine mode for 1.2 second, every 10 seconds, up to a total of two minutes. This two
phase scanning protocol was designed for imaging a ventilated rat under ‘forced’
breath hold in the first phase by turning off the ventilator and ventilated breathing in
the second phase. Chapter 3 gives further detail on animal procedures as well as the
registration of the second phase images.
The acquired two phase DCE-CT data were analyzed with CT Perfusion
software (GE Healthcare) to derive quantitative maps of total hepatic blood flow ( F t ),
hepatic arterial blood flow

(Fa),

blood volume

(Vb),

mean transit time (Tc),

permeability surface area product (PS), as well as the hepatic arterial fraction of blood
flow a.
When a bolus of contrast agent is injected into a peripheral vein, the rate of
delivery of contrast agent to the capillary network in a unit mass of tissue is
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FT-[aCa(t)+(l-a)Cpv(t)], where FT is total liver blood flow in ml/min per unit mass of
liver tissue and aCa(t)+(l-a)Cpv(t) is a weighted sum of the contrast concentration
over time in the hepatic artery (Ca) and portal vein (Cpv) with the a being the fraction
of Ft that is derived from hepatic artery. If the mass of contrast in tissue (vessels plus
Disse space) is linear with respect to the arterial concentration and Ft remains
constant in time, then the following relationship holds true as a result of linear
superimposition:
(5)
where Q(t) is the concentration of contrast in tissue over time, R(t), is the impulse
residue function (IRF), and * is the convolution operator. Q(t), Ca(t), and Cpv(t) in
equation (5) can be measured by dynamic CT scanning as described previously and
deconvolution between these two curves then yields FT-R(t), the flow-scaled impulse
residue function (See Figure 1.4). R(t) describes the mass of contrast that remains in
the tissue following bolus injection of a unit mass of contrast l05. The algorithm used
in CT Perfusion for the calculation of the functional parameters is based on the
adiabatic approximation of the Johnson-Wilson model, a hybrid compartment and
distributed parameter model with bidirectional exchange of contrast between the
intravascular space and the extra vascular space 106 107. The adiabatic approximation
assumes that the tracer concentration in parenchymal tissue changes slowly relative to
that in hepatic sinusoids. This assumption allows for a closed-form mathematical
solution to the flow-scaled impulse residue function, FT-R(t) where R(t) is defined by :
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1

R(t) = - 1.0
E e -« -^

0 < t< T a

T0< tc<Ta + Tc
t >T0 + TC

(6)

By definition, Fx-R(t) is equal to Fx(ml/min/100g) from time zero to the (vascular)
mean transit time, Tc, E is the extraction fraction 108 and k is FTE/Ve (where Ve is the
distribution volume of contrast in the Disse space). The area under the rectangular
portion of the blood flow scaled IRF corresponds to the blood volume (Vb, ml/lOOg).
Fa, the hepatic arterial blood flow is then calculated as oc-Fx while the permeability
surface area product of the liver sinusoids (PS) is calculated via the Renkin and Crone
relationship. PS=-Fln(l-E).
The calculation of perfusion parameters (T0, Ft,

Vb,

Fa and PS) described

above is applied to the unique tissue enhancement curve Q(t) corresponding to each
voxel in the DCE-CT time series. The model is fit to the measured Q(t) by searching
all parameter values and minimizing the sum of squares deviation. All parameter
values are constrained to be positive, a and E are fractions and are constrained to be
between 0 and 1. Values for the calculated perfusion parameters are then assign to
voxels corresponding to the Q(t) from which they were derived. This process
generates a two-dimensional functional map for each perfusion parameter
corresponding to each slice of the liver in the DCE-CT scan. These maps are
displayed as false color images from low (blue) to high (red) functional values.
CT Perfusion is a useful tool in the study of vascular and angiogenic changes
that occur in hepatic fibrosis and cirrhosis. It provides a non-invasive means to track
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changes in the development of liver disease, and can aid in assessing the effects of
treatment as well as prediction of clinical outcomes.

1.7

REASEARCH GOALS
The aim of this project was to evaluate the utility of CT Perfusion in the

investigation of fibrotic liver disease. In this regard the three primary goals of this
thesis were as follows:
(1) Characterize the bias, variance and covariance of perfusion parameter estimates
associated with the CT Perfusion software package.
(2) Track changes in perfusion parameters during the progression of fibrotic liver
disease in a rat CCI4 model of liver fibrosis.
(3) Correlate perfusion parameters in rats measured with CT Perfusion to hepatic
fibrosis content at various stages of liver disease.

1.8

THESIS OUTLINE
Chapter 2 presents a study investigating the CT Perfusion software package in

terms of the bias, variance and covariance associated with the perfusion parameters
estimated. Three different parameter sets corresponding to normal, mild and severe
liver disease were used for simulation. My contributions to the study were the
determination of parameters sets used, the completion of all mathematical
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calculations, setup and running of the Monte Carlo simulations, all subsequent data
analysis and interpretation, and the writing and revision of the manuscript.
Chapter 3 presents a study investigating changes in perfusion parameters in a
rat

CCI4

model of liver fibrosis in comparison to a control group. Perfusion

parameters were also correlated to histology. My contributions to this work were as
follows; the handling and treating of the animals with the assistance of a trained
animal technician; the conducting of all DCE-CT examinations and subsequent image
registration; analysis of the DCE-CT scans with CT Perfusion; performing analysis on
the derived functional maps; performing analysis of histological samples; statistical
analysis; writing and revising the manuscript.
Chapter 4 provides a summary of the findings from chapter 2 and chapter 3,
followed by concluding remarks and suggestions for future work on the evaluation of
anti-fibrotic treatments and management of fibrotic liver disease.
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Figure 1.1. Gross anatomy of the gut showing the hepatic artery (red) as well as
the portal vein and supplying vessels (blue). The portal vein supplies blood from the
spleen, gut and other mesentery, and accounts for approximately 75% of total liver
blood flow. The remaining 25% of liver blood flow is supplied from the hepatic
artery.
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<http://upload.wikimedia.Org/wikipedia/commons/3/33/Gray591 .png>
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2011.
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Figure 1.2.

Sinusoid of a rat liver with fenestrated endothelial cells. Fenestrae are

approx 100-175nm in diameter, and sinusoidal width 5 microns. Original mag 30,000.
Note the hepatocyte microvilli occupying the space of Disse. Prof. Robin Fraser.
Sinusoid. 28 March 2011. <http://en.wikipedia.0rg/wilci/File:Sinus0id.jpeg>
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Figure 1.3

The hepatic lobule. Blood flows from the portal triad (hepatic artery,

portal vein, bile duct) through the liver sinusoids to a hepatic venule. (Adopted from:
Cunningham, C.C., and Van Horn, C.G. Energy availability and alcohol-related liver
pathology. Alcohol Research & Health 27(4):281-299, 2003.)
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-k(t-To-Tc)

Figure 1.4. The blood flow scaled impulse residue function (IRF) according to the
Johnson-Wilson model with adiabatic approximation. Ft (ml/min/100g) is the blood
flow, Vb (ml/100g) is the blood volume (shaded area), E is the extraction efficiency,
Tc (seconds) is the mean transit time, k is the net back flow rate of the contrast from
the extravascular (Disse) space to the intravascular space.
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CHAPTER 2
ERROR ANALYSIS OF HEPATIC PERFUSION PARAMETERS
CALCULATED WITH CT PERFUSION
2.1

INTRODUCTION
In the past, fibrosis and cirrhosis were thought to be irreversible. Newer

understanding of the pathogensis of hepatic fibrosis1,2 has resulted in many potential
anti-fibrotic drugs such as the dual endothelin receptor antagonist, Bosentan. In order
to test the efficacy of potential anti-fibrotic drugs, a non-invasive measure of fibrosis
in animal models and eventually human clinical trials will be required.
The progressive breakdown of normal vascular structure in a cirrhotic liver is
associated with an increase in intrahepatic vascular resistance. Consequentially a
change in both regional and global perfusion takes place in the liver 3'4. Patients with
cirrhosis have been shown to have a decrease in portal hepatic blood flow (PHBF).
The decreased portal perfusion is thought to be partially balanced by an increase in
arterial hepatic blood flow (AHBF) via the hepatic arterial buffer response (HABR)5.
Lautt et. Al. originally demonstrated the HABR in the liver of cats. Richter et. al.
demonstrated this process in normal and cirrhotic rat livers and Aoki et. al. later
demonstrated it in normal and cirrhotic livers of humans. If PHBF and AHBF can be
measured non-invasively, then the change in the ratio of PHBF and AHBF could
provide a non-invasive bio-marker for hepatic fibrosis.
Liver perfusion has previously been measured with dynamic PET methods 67.
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To properly estimate both PHBF and AHBF a dual input model must be used,
requiring arterial and portal time activity curves. Due to the poor spatial resolution of
PET images, the portal activity curves cannot be obtained in a non-invasive manor 6.
Doppler ultrasound has also been investigated as a non-invasive method of
measuring hepatic blood flow 8. Doppler ultrasound measures the average velocity of
blood (cells) in a vessel, then flow is calculated using an estimate of the cross
sectional area of the vessel. This leads to two of the major drawbacks of using
Doppler ultrasound. First, blood flow can only be calculated in large vessels, so no
regional blood flow information can be obtained. Second, the measure of the cross
sectional area depends highly on the skill of the operator, which leads to large intra
observer variability 9.
Both dynamic contrast enhanced computed tomography (DCE-CT) and
magnetic resonance imaging (MRI) offer greatly improved resolution over
radioisotope techniques, eliminating the need for invasive portal venous
measurements. Completely non-invasive measurements of hepatic perfusion can be
made and have been shown to correlate well with the severity of cirrhosis 8,10,1'. MRI
has the advantage of not exposing patients to potentially harmful ionizing radiation,
however, the non-linearity between contrast agent concentration and MRI signal poses
problems for quantification.
Using either MRI or CT, several different methods of analysis have been
investigated. Miles et al 199310 proposed a simple method of measuring blood flow
based on the maximum slope of the tissue time density curve (TDC) divided by the
peak arterial concentration. Blomley et al 1995 reported a modified version that
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measures portal venous perfusion by subtracting the splenic time density curve, scaled
to represent hepatic arterial flow, from the liver tissue curve. As previously pointed
out 13 14 15 16 the maximum slope method has two shortcomings. First, the method
assumes no venous outflow of contrast at the time of maximum initial slope, which
may not always be true especially in liver disease. Second, modeling techniques allow
for the measurement of additional parameters. The maximum slope method only
determines arterial and portal venous perfusion, whereas modeling methods can
measure additional parameters such as mean vascular transit time (Tc), vascular
volume and permeability surface area product (PS). These additional parameters may
offer further insight into the development and progression of liver disease.
Matem et al. proposed a dual input compartmental model to estimate both
arterial and portal hepatic perfusion. However to achieve the perfusion estimates they
assume that the extraction fraction, E, is simply 1.0, meaning that there is no barrier to
diffusion between the vascular space and the Space of Disse. This assumption is
justified by the fenestrated endothelium of the liver sinusoids, allowing contrast agent
to freely diffuse into the extravascular space (EVS). In the normal liver this
assumption may be correct, however, capillarization of the sinusoids has been
reported in liver fibrosis and cirrhosis 17, which could limit the extraction of contrast
agent to the EVS to a varying degree.
The Johnson and Wilson two-compartment model is a good balance between
mathematical complexity and accuracy . A time domain solution (the adiabatic
approximation) has been proposed and thoroughly investigated for application with
oxygen labeled water in the brain as well as treatment planning in stroke with regular
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CT contrast 19 20. This model has recently been modified for use in the liver by
incorporating a dual blood flow source, allowing for the measurement of both PHBF
and AHBF, and validated using microspheres in rabbit liver with excellent results 15.
In contrast to the dual input model proposed by Matem et al., the dual input Johnson
and Wilson model makes no assumptions on the value of the extraction fraction.
In this study we conduct a sensitivity analysis of the model utilized in CT
perfusion (GE Healthcare), as well as Monte Carlo simulations, to investigate the
software’s utility in the investigation of fibrotic liver disease in a rat model. We
consider the normal, mild, and severe stages of liver disease. Hepatic arterial and
portal venous input functions used in the analysis and simulations were obtained from
actual DCE-CT studies on rats.

2.2 METHODS
2.2.1 Tracer Kinetics Model
Simulations were conducted using CT Perfusion (GE Healthcare). The software
utilizes the adiabatic approximation to the Johnson and Wilson model 18 described by
St. Lawrence and Lee 19. A schematic of the model is shown in Figure 2.2, where Ft is
the total hepatic blood flow, Vb is the liver blood volume, Ve is the distribution of
contrast in the extravascular space of the liver (Space of Disse) and PS is the
permeability surface area product of the endothelium of liver sinusoids. The adiabatic
approximation solution for the impulse residue function, R(t), of the Johnson and
Wilson model can be expressed as follows:
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0.0
R(t)= 1.0

0<t<T0
T0 < t < T 0 +Tc

(1)

E e -k(«-T„-Tc) t > T ( ) + T c

-PS/

where E is the extraction fraction21 defined as, E = l - e ' Ff, k=FTE/Ve is the rate
constant of the washout of contrast from the EVS to the intravascular space (IVS), To
is the time delay between the arrival o f contrast at the hepatic artery (or portal vein)
and the liver, and Tc is the mean transit time of contrast through the liver vasculature.
For organs with a single blood flow source, such as the brain, the tissue time
density curve, Q(t), is defined by Equation 2 l9. F is the blood flow and C(t) is the
time density curve of the supplying vessel.

gtt)=Fc(f)*m

(2)

For the liver, which derives its blood flow from both the hepatic artery and the portal
vein, Q(t) is the sum of the enhancement from both blood flow sources. Thus, Q(t) for
the liver becomes:

C*)='v

<:„(/).«(0

(3)

Where Fa and Ca(t) are the AHBF and the hepatic artery time density curve
respectively. Likewise Fpv and Cpv(t) are PHBF and the portal vein time density
curve. R(t) is the same for both Fa and Fpv since the same unit of tissue will have the
same impulse response function. Equation 3 can be re-written in terms of total blood
flow to give Equation 4.

QV) = Ft- [aC„(0+(l-a)C^(0]*/!(<)

(4)

Where Ft is the total hepatic blood flow and a is the fraction of total hepatic blood
□

flow from the hepatic artery.
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2.2.2 Sensitivity Analysis
Sensitivity analysis provides a more in-depth understanding of the tracer
kinetics model. We calculate the sensitivity functions of each parameter using
Equation 5 where, SFI is the sensitivity function for the ith model parameter Pt.
□

SF = M )
æ

(5)
□

Each sensitivity function represents the changes in the model output, namely the
tissue time density curve (Q(t)), from a small change in the respective parameter. The
greater the magnitude of a parameter’s sensitivity function, the more sensitive the
model output (Q(t)) is to a small change in that parameter and the estimation of that
parameter is less affected by noise in Q(t). Also the more similar the sensitivity
functions of two parameters are the harder it is to separate the parameters.

2.2.3 Covariance/Correlation Matrix
Calculating the covariance (COV) matrix is important in understanding the inherent
variance associated with estimating each of the model parameters. The COV matrix
was calculated from the Fisher information matrix, F , as explained by Huang and
Phelps and similarly used by Henderson et. al .
Each column of the Fisher information matrix is composed of a different
sensitivity function.
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The covariance matrix is:

c o v ^ ^ -F Ï

(7)

where ct is the estimate of the noise variance in the measured model output, Q(t).
The diagonal elements of the covariance matrix are the variances ( of i=Ft, a,
E, k, To and Tc) of the estimated parameters from the model. The off diagonal
elements are the covariances (ajjij=FT, a, E, k, T0 and Tc) of two estimated
parameters. The covariance matrix can be converted into the correlation matrix
Pu = - ^
a ia j

(8)

Elements of the correlation matrix are all between -1 and 1. Unity represents
perfect positive correlation and -1 is perfect negative correlation. A coefficient of zero
represents no correlation. The correlation matrix allows for an easier interpretation of
parameter interactions.

2.2.4 Monte Carlo Simulation
Three different states of disease severity were considered for simulation. Table 1
lists the parameter values for normal, mild and severe liver fibrosis. The values for a,

45
F, E, k, T0, and Tc were estimated from microsphere experiments and indicator
dilution techniques in rats 24 25 26. Total hepatic blood volume, Vb and PS were derived
from the assumed parameter values as Vb= F T c according to the Central Volume
Principle 27 28 and PS=-Frln(l-E) from the Crone relationship 21. Using the assumed
parameter values of each disease state, along with the arterial and portal venous time
density curves in Figure 2.1, the tissue TDC, Q(t), can be calculated using Equation 1
and Equation 4. Gaussian random noise, which standard deviation was equal to the
square root of Q(t), was added to the tissue TDC.
For each disease state a time series of simulated CT images were generated from
the simulated noisy curves of the corresponding tissue TDC. Each set of images
consisted of a 48x48 pixel block where the time density curve of a pixel was a
simulated noisy curve of the corresponding tissue TDC. CT Perfusion was used to
analyze each set of images to estimate the different parameters and their differences
from the ‘true’ values. This method resulted in the equivalent of 2304 simulation runs
per simulated tissue TDC. From this data the variance and bias of each estimated
parameter was determined.

3.3 RESULTS
Figure 2.3 shows the sensitivity functions calculated from Equation 1 for each
parameter of the model as well as for each disease condition, normal, mild, and
severe. Total blood flow was the most sensitive parameter followed by a , k, E, Tc,
and To respectively. The sensitivity of total blood flow increased with increasing
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disease severity while the sensitivity of a decreased. E and k both exhibited low
sensitivity in the first 30 seconds, followed by increased sensitivity in the later phase.
The mean transit time, Tc, showed decreasing sensitivity with increasing disease
severity. The sensitivity of To showed little change with disease severity.
Table 2 lists the variances of the estimated model parameters under normal,
mild, and severe disease conditions, as determined from the diagonal o f the
covariance matrix. The variances of Vb and PS were calculated from those of other
parameters using standard error propagation techniques. As disease severity increased
all estimated parameters showed a decrease in their variation except a, which showed
a slight increasing trend.
The correlation matrix was calculated for each disease severity and is shown in
Table 3. (a) was highly correlated with To for normal and mild disease states as well
as Ft for mild and sever disease states. The highest correlations were observed
between Ft and Tc as well as between E and k.
Figure 2.4 show the results from the Monte Carlo simulations. The bias is
plotted on the vertical axis and standard deviation of the added Gaussian noise on the
horizontal axis. Error bars represent the standard deviation of the estimated biases at
each level of noise. To and Vb showed little change in bias for both increasing noise
and disease severity. Bias remained stable for Tc and Ft estimates for the mild and
severe disease states but increased with noise for the normal disease state. The
accuracy of parameter estimation amongst all parameters tended to decrease with
increasing noise. The accuracy of estimating To and Tc increased with increasing
disease severity while a estimates showed decreasing accuracy with increased disease

47
severity.

3.4 DISCUSSION
To evaluate the utility of CT-Perfusion software in assessing changes in a rat
model fibrotic liver disease, we conducted a sensitivity analysis of the Johson and
Wilson model utilized by CT-Perfusion as well as performed Monte-Carlo simulations
for normal, mild and severe disease conditions as outlined in Table 1.
In the Monte-Carlo simulations To estimates were very stable, showing little
bias among all disease states and noise levels. As predicted by the covariance matrix
the variance of the estimate decreased with increasing disease level.
Monte-Carlo simulations for Tc showed a positive bias under the normal
condition. Mild and sever disease conditions showed little bias. The correlation matrix
showed a strong negative correlation between Tc and FT. In the Monte-Carlo
simulations the estimates of Ft was negatively biased for normal conditions. Thus, the
Monte Carlo simulations demonstrate the strong negative correlation between Tc and
Fj predicted by the covariance/correlation matrix. The variances of Tc and Ft in the
Monte Carlo simulations also agreed with the predictions of the covariance matrix,
both decreased with increasing disease severity.
The Vb estimates in the Monte Carlo simulations were stable among disease
states and noise levels. The mild diseased state had the largest bias but still remained
less than 10% relative to the mean. The Vb estimates also had the smallest variance of
all the estimated parameters relative to their means. This is likely because o f the
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strong negative correlation between Tc and FT. Since Vb is the product of Tc and Fb
according to the Central Volume Principle27,28, any error in one parameter would
largely be canceled out by error in the other.
Determined by Ft and E via Crone’s equation 21, PS was the least stable and
accurate of all the parameters. This should not be surprising as the covariance matrix
predicted a very large variance for the estimation of PS. As the Monte-Carlo
simulations demonstrate in Figure 2.4, constraints applied by CT Perfusion software
greatly reduce this variance. Consequentially a large bias is introduced into the
estimate. The changes in the sensitivity function of E over disease severities were the
largest among all the parameters (Figure 2.3 C). These changes in sensitivity also
affect the parameters with which E is correlated. Under normal conditions E is
partially correlated with Tc, but then becomes more closely correlated with a and Ft
as the disease severity worsens. These correlations mean that any bias in E will be
transferred to the correlated parameters. Thus, bias in the estimate of E, which is
caused by constraints intended to reduce its variance in CT Perfusion, is a major
source of bias seen in the other parameters.
The covariance matrix showed no trend in the variance of a, however, in the
Monte-Carlo simulations the variance for a increased as disease severity worsens.
This is likely due to the physiological constraint that a must be positive which is
employed by CT-Perfusion. At low values of a this constraint will affect the estimate
more than at the higher values. As a result the low a (low disease severity) estimates
have lower variance than predicted by the covariance matrix. Overall the Monte-Carlo
simulations show a stable estimate of a with disease severity and noise levels.
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Variance, although increasing with disease severity, remained reasonable. The
sensitivity function for a shows a narrow temporal window of sensitivity. Care should
be taken that no motion or other artifacts occur during this window of imaging or
large errors in the estimation of a may result.
We conducted a sensitivity analysis of the model utilized by CT-Perfusion, as
well as performed Monte-Carlo simulations for different health conditions, both
normal and abnormal, of the liver. The comparison of the theoretical estimates of
variance from the covariance matrix to the results of the Monte-Carlo simulations
highlight some of the effects of constraints used in CT-Perfusion software. While
constraining a variable can reduce its variance, this inevitably introduces a bias into
the estimate. Whenever there is a high level of correlation between parameters,
caution should be used when applying constraints. Any bias introduced by a constraint
will not only bias the constrained parameter, but can bias other correlated parameters
as well.
There are limitations in this study. First, one set of the arterial and the portal
venous time density curves from a single DCE-CT rat study was used to generate the
Monte-Carlo simulations as well as the sensitivity functions and covariance and
correlation matrices. Second, the effects of different noise levels of the input time
density curves or injection rates were not investigated. The effect of different
injection rates on compartmental models has been investigated several times before 14
.It has been concluded that slowing down the injection rate generally increases
uncertainty and bias in parameter estimation.
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Overall these simulations suggest that CT-Perfusion can accurately and
reliably measure multiple physiological parameters in the liver of the rat. One of these
parameters,

a,

being the ratio between the

Fa and Ft,

could be a sensitive parameter

for non-invasively measuring fibrosis progression in the liver.
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20

40

60
80
Time (seconds)

100

120

Time density (concentration) curves of the abdominal aorta, Ca(t), and

the portal vein, Cpv(t), acquired from a DCE- CT study on a rat scanned at 120kVp
and 80mA.
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Figure 2.2

Schematic of Jonson and Wilson model modified for dual input for the

liver. Contrast arriving from the hepatic artery Ca(t) and portal vein Cpv(t) flows into
the intravascular space. From the vascular space the contrast can diffusion into the
extravascular (Disse) space.
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Sensitivity functions for normal, mild, and severe disease conditions.

54

Figure 2.4

Results from the Monte Carlo simulations. The bias is plotted on the

vertical axis and standard deviation of the added Gaussian noise on the horizontal axis.
Error bars represent the standard deviation of the estimated parameter at each level of
noise.
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Normal
Mild
Severe

Table 2.1

a
15
25
40

Fy
200
150
125

Values Used For Sensitivity Analysis
E
k
To
Tc
0.17 0.063 4.0
8.5
0.12 0.021
4.0
10.5
0.10 0.011 4.0
10.5

vb

28.3
26.3
21.9

PS
37.3
19.2
13.2

Parameter values used for sensitivity analysis and Monte-Carlo

simulations. The values were determined form previous microsphere experiments and
indicator dilution techniques. Units are as follows: a %; Fj ml/min/lOOg; E unitless; k
min'1; T0 seconds; Tc seconds; Vb ml/lOOg; PS ml/min/lOOg.

Disease
Severity

Variance as Predicted by the Covariance Matrix
Noise
E
k
Level <x(%) Ft
To
Tc
vb PS

Normal

SD=2
SD=4
SD=6
SD=8

5.27
10.5
15.8
21.1

13.5
26.9
40.4
53.9

0.20
0.40
0.59
0.79

0.020
0.039
0.059
0.078

0.7
1.4
2.0
2.7

0.8
1.6
2.4
3.2

3.27
6.55
9.82
13.1

Mild

SD=2
SD=4
SD=6
SD=8

5.89
11.8
17.7
23.5

8.95
17.9
26.8
35.8

0.16
0.32
0.47
0.63

0.008
0.016
0.024
0.032

0.5

0.7
1.3
2.0
2.6

2.42 197.1
4.84 394.1
7.26 591.2
9.68 788.2

SD=2
SD=4
SD=6
SD=8

5.32
10.6
16.0
21.3

7.54
15.1
22.6
30.2

0.17
0.35
0.52
0.69

0.006
0.012
0.018
0.024

0.6
1.1
1.7
2.3

1.88
3.76
5.65
7.53

Severe

Table 2.2

1.0

1.5
2.0
0.3
0.7

1.0

1.3

233.2
466.3
699.5
932.7

216.3
432.6
648.9
865.2

Variances of estimated parameters for normal, mild, and severe liver

disease, as determined from the diagonal of the covariance matrix. Units are as
follows: a %; Ft ml/min/lOOg; E unitless; k min'1; To seconds; Tc seconds; Vb
ml/100g; PS ml/min/lOOg.
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Disease
Severity

Correlation Matrix
a

1.000

0.027
E 0.137
K -0.186
To 0.870
Tc -0.147
Ft

Normal

a

a

Mild

a 1.000
Fy -0.623
E 0.576
K 0.310
To 0.793
Tc 0.322
a

Severe

Table 2.3

a 1.000
Ft -0.748
E 0.690
K 0.511
To 0.570
Tc 0.420

Ft

0.027

1.000

0.264
0.222
0.476
-0.948
Ft

-0.623

1.000

-0.305
-0.116
-0.079
-0.895
Ft

-0.748

1.000

-0.534
-0.380
0.018
-0.861

E
0.137
0.264

1.000

k
-0.186
0.222
0.883

1.000

0.883
0.224
-0.500

-0.078
-0.360

E
0.576
-0.305

k
0.310
-0.116
0.908

1.000

1.000

To
0.870
0.476
0.224
-0.078

1.000

-0.554
To
0.793
-0.079
0.511
0.306

0.908
0.511
-0.086

0.306
-0.173

-0.232

E
0.690
-0.534

k
0.511
-0.380
0.939

To
0.570
0.018
0.425
0.330

1.000

0.939
0.425
0.110

1.000

0.330
0.027

1.000

1.000

-0.364

Tc
-0.147
-0.948
-0.500
-0.360
-0.554

1.000

Tc
0.322
-0.895
-0.086
-0.173
-0.232
1.000
Tc
0.420
-0.861
0.110
0.027
-0.364

1.000

Correlation matrices of estimated parameters for normal, mild, and

severe liver disease. Elements of the correlation matrix are all between -1 and 1.
Unity represents perfect positive correlation and -1 is perfect negative correlation. A
coefficient of zero represents no correlation.
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CHAPTER3
IN-VIVO MONITORING OF THE DEVELOPMENT AND PROGRESSION
OF HEPATIC FIBROSIS IN A CCL, RAT MODEL WITH CT PERFUSION
3.1

INTRODUCTION
With an increased understanding of the mechanism of fibrosis in response to

chronic liver injury1, potential anti-fibrotic drugs have been proposed and
demonstrated the reversal of liver fibrosis in-vitro and in-vivo2 3 4. To effectively test
these drugs, both in animals and eventually in clinical trials, a repeatable measure of
fibrosis progression will be required.
The staging of fibrosis is also an important factor in treatment planning.
Patients with hepatitis C virus have been shown to benefit from antiviral therapy
however; interferon treatment is not without its complications

r

/

*7

. Thus, therapy is

reserved for those who have already shown a marked progression of liver disease.
Currently patients with a METAVIR score of F2 or F3 are classified as having
‘clinically significant’ fibrosis meaning they are at higher risk for developing cirrhosis
and it’s subsequent complications. Thus, patients with clinically significant fibrosis
have a higher indication for anti-viral treatment than patients with no, or minimal
fibrosis (METAVIR F0/F1) 9 l0. Patients with the highest METAVIR score of F4
should be monitored and treated for cirrhosis related complications such as, portal
hypertension and hepatocellular carcinoma.
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Liver biopsy is currently the gold standard for assessing fibrosis, however it is
not without limitations. Histological grading is not reproducible; there are both intraand inter-observer variability on small sized or fragmented biopsy samples11. In
addition the biopsy procedure can be painful and carries a risk of serious
complications , greatly reducing patients’ willingness to participate in clinical trials.
Because of these limitations, biopsy is an impractical method for the regular
monitoring of liver fibrosis required for the evaluation of new anti-fibrotic treatments
as well as treatment planning.
In response to this need, many noninvasive methods for monitoring hepatic
fibrosis have been proposed; of which the most thoroughly investigated is serum
markers. Both direct serum markers, such as hyaluronate, and indirect serum markers
such as alanine transaminase (ALT) and aspartate transaminase (AST) have been
investigated 13 14 15 16 I7. When only direct or indirect markers are used individually
they can reasonably diagnosis or exclude cirrhosis but lack the ability to differentiate
intermediate stages of fibrosis. Thus newer algorithms, combining multiple markers,
such as Fibrotest or the Enhanced Liver Fibrosis (ELF) test have been proposed to
improve diagnostic accuracy. In a meta-analysis Fibrotest was able to distinguish
between METAVIR stages ^F1 vs

or ‘clinically significant’ fibrosis with

AUROC of .84 .A limitation of direct liver markers is that they are not liver specific
thus; they require patient specific considerations to be taken into account when
interpreting the results. Currently, the ability to measure direct markers is not
routinely available in most hospitals.
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Non-invasive imaging methods for staging of liver fibrosis have been
proposed as well. Some of these include, diffusion-weighted magnetic resonance
(MR)

, liver stiffness measurement (LSM) techniques such as transient

elastography22,23 and MR elastography24 25 26, as well as perfusion imaging 27'29.
The goal of perfusion imaging in the liver is to track changes in the hepatic
microvasculature. Chronic liver disease, regardless of the etiology, leads to the
“activation” of hepatic stellate cells30. This activation results in the transition of the
quiescent hepatic stellate cells to a proliferative, fibrogenic, and contractile
myofibroblast-like phenotype. The contractility of the activated hepatic stellate cells,
as well as the resulting fibro-genesis and collagen deposition, disrupts the normal
sinusoidal vasculature. Consequentially, an increase in blood flow resistance is
observed leading to decreased portal blood perfusion and portal hypertension31.
In this regard the aim of our study was to correlate the perfusion parameters
calculated using CT-Perfusion (GE Healthcare) in the liver of the rat, to the amount of
liver fibrosis determined by digital image analysis of stained excised liver sections.

3.2

METHODS

3.2.1 Animal Model
Male Sprague-Dawley rats (300g - 350g) were randomized into control and
treated groups. To induce liver cirrhosis, the treated group (n=9) received
intraperitoneal injections of carbon tetra-chloride (CCI4) three times a week at a dose
of 0.15ml/kg diluted 1:6 in olive oil. Phénobarbital (0.04g/L) was also added to the
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drinking water of the CCI4 treated animals to further potentiate liver damage 32. The
control group (n=6) received intraperitoneal saline injections three times a week.
Dynamic contrast enhance computed tomography (DCE-CT) scans, as described
below, were performed on all animals at baseline and after 2, 4, 6, and 8 weeks of
treatment. After 8 weeks of treatment all animals were euthanized. Livers were
removed and fixed in 10% buffered formalin for histological examination.
To obtain histology samples at intermediate disease levels two groups of rats
were treated with CCI4 and phénobarbital as described above. The first group (n=5)
received treatment for 4 weeks and the second group (n=5) received treatment for 6
weeks. After the respective 4 and 6 weeks of treatment, DCE-CT scans were
performed. The animals were then euthanized and livers were removed for
histological analysis.

3.2.2 Animal Preparation
Animals were initially sedated with 3% isoflurane. Once sedated, a catheter was
inserted into the tail vein. 35mg/kg of pentobarbital was then administered via intra
venous (IV) injection and isoflurane anesthesia was discontinued. Animals were then
intubated and placed in a supine position of the CT bed where they were mechanically
ventilated on oxygen at a rate of approximately 80 breaths per minute. To facilitate a
breath hold, 0.1ml/kg of the paralytic, pancuronium, was administered IV just prior to
imaging. CO2 and O2 levels were monitored using a pulse oximeter. PCO2 was
maintained at 40+/-2 mm Hg and O2 saturation was maintained above 98%.
Temperature was monitored via rectal probe and maintained at 37.5 +/- 0.5C with a
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re-circulating heated water blanket. Supplemental doses (5mg/kg) of pentobarbital
were administered IV as required during the experiment.

3.2.3 Imaging
DCE-CT scans were performed using a clinical GE multi-slice CT scanner
(Discovery VCT, GE Healthcare). A localization scan was first performed to place
eight 5mm slices covering the entire liver. After the scan location was selected the
DCE-CT scan was conducted in two phases. In the first phase, images were acquired
in cine mode with a tube voltage and current of 120kVp and 80mA respectively and a
gantry speed of one rotation per second. Images were reconstructed using the detail
filter and a temporal resolution of 0.45 seconds. Total time for the first phase cine
scan was 34 seconds. At the beginning of the scan lml/kg of an iodinated contrast
agent (Omnipaque 300mgl/ml) was injected via the tail vein catheter over 4s. During
the entire first phase the ventilator was turned off to simulate a breath hold and
eliminate any respiratory motion in the liver.
In the second phase the ventilator was turned on (80 breaths per minute) and
animals were scanned in cine mode for 1.2 seconds, every 10 seconds, up to a total of
two minutes. After completion of the scan, images from the second phase were
retrospectively gated to match the first phase images. Using the first phase images, a
region of interest was drawn at the level of the diaphragm. From the 16 images in each
of the second phase cine scans, the image that best matches the first phase images
(acquired with breath hold) was manually selected based on image intensity. This
proved to be a simple manual registration requiring only a few minutes to complete
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per study. The smooth second phase of the portal venous and aortic time density
curves demonstrate the aptitude of the retrospective gating method (Figure 3.1).

3.2.4 CTPerfusion Measurements/Data Analysis
CT images were analyzed using CT Perfusion software, which utilizes a dual
input hybrid, compartment and distributed parameter, model. This model has been
previously described and validated with microspheres in the rabbit liver 33. As
expressed in equation (1), a weighted sum of the aortic, Ca(t), and portal venous,
Cpv(t), time density curves (TDC) were deconvolved against the liver parenchyma
TDC, Q(t), in CT Perfusion (GE Healthcare) on a pixel-by-pixel basis to obtain the
impulse residue function (IRF) 34 35 from which hepatic hemodynamic parameters are
derived as explained below. The abdominal aorta was used as a surrogate for the
hepatic artery due to its small size. Equation (2) defines the IRF, R(t)

( 1)

0.0
0 < t < T0
R(t) = «1.0
T0 < t < T 0 +Tc
Ee-k(«-T0-Tc) t > T0 + Tc

2

( )

Ft is the total hepatic blood flow, a is the fraction of total hepatic blood flow
that is derived from the hepatic artery and thus, the hepatic arterial blood flow (Fa) is
calculated as a-Fj. E is the extraction fraction of the contrast agent to the extra
vascular space, k is the net back flow rate of the contrast from the extravascular space
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to the intravascular space defined as k= FyE/Ve, where Ve is the extra vascular
volume. Tc is the mean transit time of the contrast agent from the arterial side to the
venous side. To is the appearance time of the contrast agent in the parenchyma relative
to that of the aorta. Blood volume (Vb) is calculated as the product FrT c via the
Central Volume Principle. The permeability surface area product (PS) is calculated
from the Crone relationship as PS=-Frln(l-E )36.
Perfusion weighted (PW) maps were generated for each CT-Perfusion study by
averaging the images in the first phase of each scan. In the PW maps the hepatic artery
and portal vein branches appeared hyper-dense while the hepatic veins appeared hypodense. Using custom software (IDL v6.0; RSI Inc., CO, USA) a region of interest
(ROI) was drawn on each PW map to encompass as much liver parenchyma as
possible while avoiding large vessels. Measurements were obtained by applying the
set of liver ROIs for each study to its respective functional maps (Ft, Fa, a, Vb, Tc, PS)
generated by CT-Perfusion.

3.2.5 Histological Analysis
After the final CT examination, rats were sacrificed with sodium pentobarbital
overdose. Livers were removed and fixed in 10% buffered formalin. Multiple liver
lobes were collected and embedded in paraffin and 5 pm thick slices were obtained for
histological analysis. The slices were then stained with methyl blue and mounted on
slides. The slides were digitized using an Aperio Scan Scope system (Aperio
Technologies Inc., Vista, Ca, USA). Twelve images with an individual area of
approximately 5mm were collected over multiple liver lobes of each rat. The ImageJ
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software package 37 was used to measure percent positive area of stained collagen
(PPAC). Thresholds were automatically determined using the maximum entropy
method . An example of a fibrotic liver stained with methyl blue is shown in Figure
3.3(A) and the resulting PPAC determined with Image J in Figure 3.3(B).

3.2.6 Statistical Analysis
Statistical analysis was performed using SPSS software (SPSS Inc., Chicago,
IL, USA). A Mixed Model ANOVA was used as an omnibus test to identify
significant differences between the control and CC14 treated groups. Student t-tests
with Bonferroni correction were used for post-hoc analysis of differences. To assess
differences in PPAC between control rats and rats treated with CC14 for 4, 6 and 8
weeks, independent unpaired t-tests for unequal variances were used. The Spearman
correlation method was used to evaluate the relationship between the PPAC and a. A
P-value <0.05 was regarded as statistically significant.

3.3

RESULTS
CT imaging and subsequent analysis was successfully performed in all animals

at all time points. None of the rats suffered any obvious adverse effects from the CC14
treatment nor did they develop any complication such as acities.
Liver samples in 3 animals (one treated with CC14 for 6 week and 2 treated
with CCL4 for 8 weeks) were not adequately fixed and thus, subsequent staining and
digital image analysis could not be performed. For the other 22 rats (6 treated with
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saline for 8 weeks and 6, 5, 8 treated with CC14 for 4, 6, and 8 weeks respectively)
PPAC was quickly and easily assessed. The mean PPAC for saline treated animals
was 0.37%. The mean PPAC for animals treated with CC14 was as follows; four
weeks of treatment, 1.74%; 6 weeks of treatment, 2.31%; eight weeks of treatment,
2.20%. The PPAC of animals treated with CC14 for 4, 6 and, 8 weeks were all
significantly higher than controls (P<0.002). However weeks 4, 6 and, 8 were not
significantly different from each other.
Figures 3.4 through 3.9 show measurements of Ft, Fa, a, Vb, Tc, and PS
respectively over 8 weeks of treatment with either saline (control) or CC14 (treated).
The mixed model analysis showed that CC14 treatment had a significant effect on Ft,
Fa, a, and Vb but not Tc. PS showed a non-significant trend of increase with time in
the treated group
Post hoc analysis using a two-tailed student t-test with Bonferroni correction
showed significant differences in

F t,

Fa, a, and Vb between control and treated

animals. There was a significant difference in Ft between control and CC14 treated
animals at weeks 6 and 8, as well as between CC14 treated animals at week 0
(baseline) and week 8. Fa showed a significant difference between treated and control
animals at week 6. a showed a significant difference between control and CC14
treated animals at weeks 4, 6 and, 8. a of CC14 treated animals at weeks 4, 6, and 8
were also significantly higher from the baseline value. Vb for CC14 treated animals at
week 8 was significantly lower than baseline value and that of control animals at week

8.
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A substantial correlation (r=.82 p<.00001) was observed between a and PPAC
and is shown in Figure 3.10. All other perfusion parameters showed a low (r < 0.5)
correlation with PPAC.

3.4

DISCUSSION
Digital image analysis was used in this study as a quantitative method for

assessing liver fibrosis in excised liver sections. The common histopathological
methods of assessing fibrosis has been the METAVIR staging system . METAVIR
O

was designed for the prognostic evaluation of biopsy from hepatitis C patients.
Categorical staging methods place a larger emphasis on the patterns and structures
present than the actual extent of fibrosis and are thus limited by their semi-quantitative
nature as well as inter-observer variability. In contrast to this, digital image analysis
uses a continuous variable and has implicitly high reproducibility and accuracy39.
Of all the perfusion parameters only a showed a strong correlation (r=0.82
PO.OOOOl) with PPAC (Figure 3.10). The increase in a is caused by the hepatic
arterial buffer response (HABR). As resistance to blood flow increases with collagen
deposition as fibrosis progresses, portal blood flow has been shown to decrease. It is
suspected that decreased washout of adenosine, a vasodilator, caused by decreased
portal blood flow mediates an increase in hepatic arterial blood flow31. Thus, a, which
is the ratio of Fa/Fr, increases with disease severity and may potentially be an
excellent biomarker for liver fibrosis.
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The CC14 model of liver fibrosis used in this study is common and has been
well explored 40. Over the 8 weeks of treatment, liver fibrosis progressed from normal
liver architecture to portal fibrosis with few septae and finally bridging fibrosis and
cirrhosis (Figure 3.3). Only three of the treated animals developed cirrhosis. Although
Ft and Vb did not correlate well with PPAC treated animals had significantly lower
values than control animals after 8 weeks of treatment. While a seems to be a good
biomarker for moderate fibrosis, Fj and Vb may be good biomarkers for predicting
cirrhosis which was starting to develop in our model. Other perfusion studies of
cirrhotic liver disease have found similar decreases in Ft and Vb41,42. Multiple
biomarkers of different stages of liver disease may be useful for staging. Similar to
serum marker algorithms, combinations of perfusion parameters could improve
diagnostic performance and warrant further investigation.
The use of mechanical ventilation along with a paralytic agent allowed for a
simulated breath hold in the animal. Along with a simple and fast manual registration
technique almost all motion was eliminated from the cine scan. While this
methodology cannot be used in patients, novel registration methods have the potential
to substantially reduce breathing motion and noise respectively in clinical practice43.
In our study the histological samples were not precisely matched to the
location of perfusion analysis. Although liver disease is generally thought of as a
diffuse disease, some heterogeneity has been shown to occur". Thus, correlation of
PPAC and perfusion parameters may have been improved if an exact match between
the area analyzed at CT examination and histological samples could be obtained.
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DCE-CT imaging carries with it the inherent risks of cancer
induction/mortality and nephrotoxicity from ionizing radiation and iodinated contrast
agents used in the study. Repeated imaging of the same location required for DCE
imaging techniques can lead to high effective doses of typically 15-20 mSv in
patients. However, newer iterative reconstruction techniques can reduce the effective
dose by several fold. 44 45
DCE-MR offers a solution to radiation dose but has it’s own drawbacks.
Compared to DCE-CT, DCE-MR has a lower spatial resolution. Additionally,
velocity-induced signal intensity changes in larger vessels has created difficulties
in obtaining quantitative perfusion data with DCE-MR 46 47.
For this study we used a commercially available dual input hybrid,
compartment and distributed parameter, model (CT-Perfusion, GE Healthcare,
Waukesha,WI, USA). Several different methods for the measurement of liver
perfusion have previously been proposed 48 29. However, discrepancies between
models used for perfusion analysis have been demonstrated 49. Choice of method for
the estimation of perfusion parameters must be assessed for each application. Models,
and respective assumptions, must be applicable to the physiology of both the normal
and disease states. Ideally, in-vivo validation of perfusion parameters against a non
model based gold standard would allow quantitative evaluation of various models. To
this effect, microspheres have been used to validate hepatic arterial and portal venous
blood flow in the liver 33 29. While these methods allow validation of blood flow other
perfusion parameters such as blood (or distribution) volume, Tc and PS currently lack
a strong reference standard for validation. Until all perfusion parameters can be
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reliably validated, under normal and disease states, the utility of various models will
depend largely on their diagnostic capability and availability.
In conclusion this study showed that perfusion parameters estimated with CTPerfusion correlated with fibrosis content determined by digital image analysis. In
particular, a, correlated very well (r=0.82 PO.OOOOl) with the progression of fibrosis
and significant changes in Ft and Vb were observed when rats progressed to cirrhosis.
These result show that CT-Perfusion is a useful method for quantifying hepatic
fibrosis and subsequent progression to cirrhosis.
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Figure 3.1

Concentration time curves from the abdominal aorta, Ca(t), and the

portal vein, Cpv(t), acquired from actual CT data of a rat. The smooth nature of the
second phase demonstrates the aptitude of the registration method used.
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C o n tro l

Figure 3.2

4 W eeks C C I4

8 W eeks C C I4

Example of Regions Of Interest (ROI) drawn for measurement of

perfusion parameters. Care was taken to include as much liver parenchyma as possible
while excluding large vessels. Histology was stained with methyl blue for collagen.
Decreased hepatic blood flow (Ft) and blood volume (Vb) can been seen after 8 weeks
of treatment. And increase in arterial fraction of blood flow (a) can be seen after only
4 weeks of treatment.
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Figure 3.3

An example of quantification of liver fibrosis with digital image

analysis. Sample image used for quantification (top) and 8-bit converted imaged for
digital image analysis (bottom). Red area corresponds to the percent positive area of
collagen (PPAC). In this example PPAC was 2.9% of the total area.
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Figure 3.4

Weeks of Treatment

Total hepatic perfusion measured in rats treated with

CCI4

and saline

over 8 weeks of treatment. (*significant difference from treated baseline; #significant
difference from control)

0

Figure 3.5

2

4

Weeks of Treatment

6

8

Hepatic arterial blood flow measured in rats treated with CCI4 and

saline over 8 weeks of treatment. (* significant different from treated baseline)
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0

Figure 3.6

2

4

Weeks of Treatment

6

8

Hepatic arterial fraction of blood flow measured in rats treated with

CC14 and saline over 8 weeks of treatment. (*significant difference from treated
baseline; #significant difference from control)

Figure 3.7

Weeks of Treatment

Blood volume measured in rats treated with CCI4 and saline over 8

weeks of treatment, (♦ significant difference from treated baseline; #significant
difference from control)
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Figure 3.8

2

4

Weeks of Treatment

6

8

Mean vascular transit time measured in rats treated with CCU and

saline over 8 weeks of treatment.

Figure 3.9

Weeks of Treatment

Permeability surface area measured in rats treated with CCI4 and saline

over 8 weeks of treatment.
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Figure 3.10 Correlation between hepatic arterial fraction and percent positive area
of collagen (PPAC) from digital image analysis of liver specimens. Spearman
correlation coefficient, r=0.82 PO.OOOOl.
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CHAPTER 4
SUMMARY AND FUTURE WORKS
4.1

SUMMARY
The primary objective of this thesis was to evaluate the utility of dynamic

contrast enhanced computed tomography (DCE-CT) imaging in conjunction with CT
Perfusion (GE Healthcare) for the investigation of fibrotic liver disease. Monte Carlo
simulations and sensitivity analysis were used to characterize the bias, variance and
covariance of perfusion parameters calculated with CT Perfusion. DCE-CT scans
were performed bi-weekly on rats treated with peritoneal injections of CC14 to induce
liver fibrosis and, by eight weeks of treatment, cirrhosis. Sham injected (control) rats
were similarly imaged for comparison. The perfusion parameters: total hepatic blood
flow

( F t ),

hepatic arterial blood flow (Fa), blood volume (V b ), mean vascular transit

time (Tc), hepatic arterial fraction of blood flow (a), and permeability surface area
(PS), were then derived from the DCE-CT scans using CT Perfusion. As treatment
progressed, CC14 treated rats showed significant changes in perfusion parameters.
Histological samples stained with methyl blue were collected at various stages of
treatment. From these stained samples liver fibrosis was quantified with digital image
analysis and correlated to perfusion parameters. A strong correlation was found
between fibrosis content and hepatic arterial fraction of blood flow (a).
The next sections summarize results obtained in each set of experiments
completed in this thesis; followed by a discussion of the experimental and clinical

83
relevance of all major findings. Monte Carlo simulations demonstrated reasonable
bias and variance in perfusion parameter estimates. In addition we were able to
illustrate significant changes in FT, Vb, Fa, and a as fibrosis progressed in a CCI4 rat
model. This demonstrates the ability of DCE-CT imaging with CT Perfusion to
quantitatively assess changes associated with vascular changes known to occur during
the development of cirrhosis

. The chapter concludes with a discussion on potential

avenues of further research.

4.2

ERROR ANALYSIS OF HEPATIC PERFUSION PARAMETERS

CALCULATED WITH CT PERFUSION
Chapter 2 presents the results of the sensitivity analysis of perfusion parameters
estimated with CT Perfusion software. Results of the Monte Carlo simulations are
presented for normal, mild, and severe stages of liver fibrosis. All sensitivity and
Monte Carlo simulations were conducted using hepatic arterial and portal venous
input functions obtained from actual DCE-CT studies on rats. Sensitivity analysis
showed that Ft was the most sensitive parameter followed by a, k, E, Tc, and To
respectively. Subsequent calculation of the correlation matrix showed high correlation
between Ft and Tc. Monte Carlo simulations showed that the accuracy of parameter
estimation amongst all parameters tended to decrease with increasing noise.
To and Vb showed little change in bias for both increasing noise and disease
severity. Bias remained stable for Tc and Ft estimates for the mild and severe disease
states but increased with noise for the normal disease state. The accuracy of
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estimating To and Tc increased with increasing disease severity.
An interesting observation was the effect of constraints imposed by CT
Perfusion software on the parameter estimates. These constraints imposed a bias on
the parameter estimates, as could be seen in the Monte Carlo simulations. Of
particular note, the bias over varying disease levels was inconsistent for Ft, Tc, and
PS. This inconsistent bias could affect the ability to measure changes in perfusion
parameters as liver disease progresses. Other parameter estimates such as Vb and a
were accurate and consistent among all levels of disease severity.

4.3

IN-VIVO MONITORING OF THE DEVELOPMENT AND

PROGRESSION OF HEPATIC FIBROSIS IN A CC14 RAT MODEL WITH CT
PERFUSION
Chapter 3 presents a study tracking changes in perfusion parameters in a CCI4
rat model of liver fibrosis. Animals were randomized into control (n=6) and CCI4
treated (n=9) groups. Dynamic contrast enhance computed tomography (DCE-CT)
scans were performed on all animals at baseline and after 2, 4, 6, and 8 weeks of
treatment. After 8 weeks of treatment all animals were euthanized and livers were
removed and stained for fibrosis with methyl blue. To obtain histology samples at
intermediate levels of progression two additional groups of rats were treated with
CCI4. The first group (n=5) received treatment for 4 weeks and the second group
(n=5) received treatment for 6 weeks. DCE-CT scans were performed in these two
shorter treatment groups at the same time points as the first, 8-week treatment, group,
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animals were euthanized and livers were removed for histological analysis at the end
of experiment.
The DCE-CT scans were analysed with CT Perfusion software and the
perfusion parameters, Fj, Fa, Vb, Tc, a, and PS were measured. Mixed model analysis
showed that CCI4 treatment had a significant effect on Ft, Fa, a, and Vb but not Tc or
PS. Post hoc analysis using a two-tailed student t-test with Bonferroni correction
showed significant differences in

F t,

Fa, a, and Vb between control and treated

animals. Digital image analysis was used to measure percent positive area of stained
collagen (PPAC). A substantial correlation (r=.82 p<.00001) was observed between a
and PPAC. All other perfusion parameters showed a low (r < 0.5) correlation with
PPAC. The strong correlation between a and PPAC suggests that a is a sensitive
biomarker of fibrosis progression in the liver. CT-Perfusion proved to be an effective
tool for tracking known vascular changes associated with the development of cirrhosis
in an animal model.

4.4

EXPERIMENTAL AND CLINICAL RELEVENCE
t

The studies completed in this thesis have a number of implications
experimentally. In the first study the variance, bias and correlation of perfusion
parameters calculated with CT Perfusion were characterized for the analysis of liver
disease. Results of this study are applicable to the interpretation of rat and possibly
patient liver DCE-CT studies analyzed with CT Perfusion.
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In the second study a CT imaging method for measuring changes in perfusion
parameters in a CCI4 rat model of liver fibrosis was developed. Because of the noninvasive nature of the imaging method, repeat measurements can be made in the same
subject. Furthermore, the CT hardware and relevant software used are widely
available. The ability of CT Perfusion to rapidly and accurately assess tissue
hemodynamics makes the methodology developed in this thesis useful for
investigating liver diseases involving vascular changes of the liver. Of particular note
would be cancer and ischemia/reperfusion injury in pre-clinical models.
The methods used in this thesis could be readily advanced to clinical use. The
DCE-CT scanning protocol used the combination of a paralytic and a ventilator,
allowing for a simple registration method to reduce motion and noise in the data set.
This methodology is impractical in the clinical setting however, registration
techniques and iterative reconstruction methods currently under development4 5 could
sufficiently reduce noise to acceptable levels. Radiation dose would not be a barrier to
clinical implementation. DCE-CT imaging results in an effective dose to the subject
of 15-20 mSv which, is similar to current clinical three-phase liver scans6.

4.5

FUTURE WORKS
The presented studies show the potential of using DCE-CT with CT Perfusion

to longitudinally follow hemodynamic changes associated with the progression of
fibrotic liver disease. With an increased understanding of the mechanisms of fibrosis,
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new treatment options are becoming available . Future studies could use the methods
n

developed in this thesis to aid in the assessment of potential anti-fibrotic treatments.
CT Perfusion has also been effectively used to study cancers of the liver .
O

Since 80% of hepatocellular carcinoma (HCC) occur in a cirrhotic background 9 a
cirrhosis/HCC model would be of particular interest. A Dimethylnitrosamine model is
capable of producing fibrosis and cirrhosis in rats and eventually HCC 10. The
methods developed in this thesis would be ideal for studying such a model, as well as
evaluating potential anti-angiogenic treatments on both the development of cirrhosis
and HCC.

4.6

LIMITATIONS
There are a few limitations to these studies. Parameters used for simulation

and sensitivity analysis were only appropriate for the study of rat liver. The results
can not be applied to studies in humans or other animal models where hepatic
perfusion parameters differ.
Histological samples were not precisely matched to the location of perfusion
analysis. Although liver disease is generally thought of as a diffuse disease, some
heterogeneity has been shown to occur 11. Thus, correlation of PPAC and perfusion
parameters may have been improved if an exact match between the area analyzed at
CT examination and histological samples could be obtained.
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Although the

CCI4

rat model of liver fibrosis is commonly used and well

understood it has no direct human counterpart. The changes in perfusion parameters
noted in the CCI4 model may differ in alternative models of liver disease.

4.7

CONCLUSIONS
The most significant conclusions of this thesis are listed below:
1) DCE-CT with CT Perfusion can track changes in hepatic hemodynamics
associated with the development of fibrotic liver disease.
2) The hepatic arterial fraction of blood flow is strongly correlated with liver
collagen content in a CCI4 rat model of liver fibrosis.
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APPENDIX A

Ja n u a ry 29, 2007
"T h is is the O riginal A p p ro va l for this protocol*
*A Full Protocol submission will be required in 2011*
D ear Dr. Lee:
Y o u r Animal Use Protocol form entitled:

Perfusion and Lipid Imaging with a Liver Specific C T Contrast Agent to Detect Progression of Cirrhosis
Funding Agency CIHR - applied for
has been approved by the University Council on Animal Care. This approval is valid from January 29, 2007 to
Th e protocol number for this project is #2007-02jMi and replaced #2005-051-07 (pilot).

January 31, 2008.

1. This number must be indicated when ordering animals for this project
2. Animals for other projects may not be ordered under this number.
3. If no number appears please contact this office when grant approval is received.
If the application for funding is not successful and you wish to proceed with the project, request that an internal
scientific peer review be performed by the Animal Use Subcommittee office.
4. Purchases of animals other than through this system must be cleared through the A C V S office. Health
certificates will be required.
A N IM A L S A P P R O V E D F O R 1 Y R .

Rat

O the r Detail

Strain

S pecies

Sprague Dawley

-2 0 0 gm

Male

Pain
Level

A n im al # To tal
fo r 1 Year

C

16

S T A N D A R D O P E R A T IN G P R O C E D U R E S
Procedures in this protocol should be carried out according to the following S O P s. Please contact the Animal Use
Subcommittee office (661-2111 ext. 86770) in case of difficulties or if you require copies.
S O P 's are also available at htto://www.uwo.ca/animat/acvs
310 Holding Period Post-Admission
320 Euthanasia
321 Criteria for Early Euthanasia/Rodents
330 Post-Operative Care/Rodent
\
343 Surgical Prep/Rodent/Recovery Surgery
R E Q U IR E M E N T S / C O M M E N T S
Please ensure that individual(s) performing procedures on live animals, as described in this protocol, are familiar
with the contents of this document.

c.c. Approved Protocol
Approval Letter
V/

The University of Western Ontario
Animal Use Subcommittee/University Council on Animal Care
Health Sciences Centre • London. Ontario • CANADA - N6A 5C1
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02 . 01.2010

*This is the 3rd Renewal of this protocol
*A Full Protocol submission will be required in 01.31.2011

Dear Dr. Lee

Your Animal Use Protocol form entitled:

Perfusion and lipid imaging with a liver specific C T contrast agent to detect progression of
cirrhosis

has had its yearly renewal approved by the Animal Use Subcommittee.
This approval is valid from 02.01.2010 to 01.31.2011
The protocol number for this project remains as 2007-028
1. This number must be indicated when ordering animals for this project.
2. Animals for other projects may not be ordered under this number.
3. If no number appears please contact this office when grant approval is received.
If the application for funding is not successful and you wish to proceed with the project, request that an internal
scientific peer review be performed by the Animal Use Subcommittee office.
4. Purchases of animals other than through this system must be cleared through the ACVS office. Health
certificates will be required.

REQUIREM ENTS/COMM ENTS
Please ensure that individual(s) performing procedures on live animals, as described in this protocol, are familiar
with the contents of this document.

The holder of this Animal Use Protocol is responsible to ensure that all associated safety
components (biosafety, radiation safety, general laboratory safety) comply with institutional safety
standards and have received ai! necessary approvals. Please consult directly with your
institutional safety officers.

c.c.

The University o f Western Ontario

Animal Use Subcommittee / University Council onAnimal Care
Health Sciences Centre, • London, Ontario • CANADA-N6A 5C1

